Vocal fold injection augmentation with Novielle voice gel

Jacqueline Allen, Jan Pryor, Rebecca J Leonard, Peter C Belafsky

Research output: Contribution to journalArticle

Abstract

Objectives/Hypothesis: There are several implants available for injection medialization of the vocal folds. None are ideal. The purpose of this investigation is to evaluate the safety and efficacy of a new FDA-approved implant for injection augmentation of the vocal folds (Novielle, Coapt Systems Inc, Palo Alto, CA). Study Design: Prospective Cohort Methodology: Individuals undergoing injection augmentation of the vocal folds with Novielle from April 2008 to present were prospectively evaluated and followed. Patients underwent strobovideolaryngoscopy, acoustic analysis, and vocal assessment with the 10-item Voice Handicap Index. Pre- and post-injection data was compared with the matched-pairs ttest. Results: 31 patients were prospectively evaluated. The mean age of the cohort was 68 years. Sixtyone percent was male. The diagnoses were 18 unilateral vocal fold paralyses, 4 vocal fold pareses, 9 presbylarynx. The mean VHI at entry was 27 (+/- 7.4). This improved to a mean VHI of 18 (+/- 9) at one month postoperatively (p < 0.00) and 19 (+/- 11) at three months (p=0.00). The mean follow-up time was 93 days. There was no evidence of adverse reaction to the implant or procedurerelated complications. Conclusion: Initial data suggests that Novielle Voice Gel is a safe and effective implant for medialization of the vocal folds. Intermediate and long-term follow-up is necessary to ensure enduring safety and efficacy.

Original languageEnglish (US)
JournalLaryngoscope
Volume119
Issue numberSUPPL.3
DOIs
StatePublished - 2009

Fingerprint

Vocal Cords
Gels
Injections
Safety
Paresis
Acoustics
Paralysis
Prospective Studies

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Vocal fold injection augmentation with Novielle voice gel. / Allen, Jacqueline; Pryor, Jan; Leonard, Rebecca J; Belafsky, Peter C.

In: Laryngoscope, Vol. 119, No. SUPPL.3, 2009.

Research output: Contribution to journalArticle

@article{04fbce3233064a789251d2c76270b82f,
title = "Vocal fold injection augmentation with Novielle voice gel",
abstract = "Objectives/Hypothesis: There are several implants available for injection medialization of the vocal folds. None are ideal. The purpose of this investigation is to evaluate the safety and efficacy of a new FDA-approved implant for injection augmentation of the vocal folds (Novielle, Coapt Systems Inc, Palo Alto, CA). Study Design: Prospective Cohort Methodology: Individuals undergoing injection augmentation of the vocal folds with Novielle from April 2008 to present were prospectively evaluated and followed. Patients underwent strobovideolaryngoscopy, acoustic analysis, and vocal assessment with the 10-item Voice Handicap Index. Pre- and post-injection data was compared with the matched-pairs ttest. Results: 31 patients were prospectively evaluated. The mean age of the cohort was 68 years. Sixtyone percent was male. The diagnoses were 18 unilateral vocal fold paralyses, 4 vocal fold pareses, 9 presbylarynx. The mean VHI at entry was 27 (+/- 7.4). This improved to a mean VHI of 18 (+/- 9) at one month postoperatively (p < 0.00) and 19 (+/- 11) at three months (p=0.00). The mean follow-up time was 93 days. There was no evidence of adverse reaction to the implant or procedurerelated complications. Conclusion: Initial data suggests that Novielle Voice Gel is a safe and effective implant for medialization of the vocal folds. Intermediate and long-term follow-up is necessary to ensure enduring safety and efficacy.",
author = "Jacqueline Allen and Jan Pryor and Leonard, {Rebecca J} and Belafsky, {Peter C}",
year = "2009",
doi = "10.1002/lary.21518",
language = "English (US)",
volume = "119",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",
number = "SUPPL.3",

}

TY - JOUR

T1 - Vocal fold injection augmentation with Novielle voice gel

AU - Allen, Jacqueline

AU - Pryor, Jan

AU - Leonard, Rebecca J

AU - Belafsky, Peter C

PY - 2009

Y1 - 2009

N2 - Objectives/Hypothesis: There are several implants available for injection medialization of the vocal folds. None are ideal. The purpose of this investigation is to evaluate the safety and efficacy of a new FDA-approved implant for injection augmentation of the vocal folds (Novielle, Coapt Systems Inc, Palo Alto, CA). Study Design: Prospective Cohort Methodology: Individuals undergoing injection augmentation of the vocal folds with Novielle from April 2008 to present were prospectively evaluated and followed. Patients underwent strobovideolaryngoscopy, acoustic analysis, and vocal assessment with the 10-item Voice Handicap Index. Pre- and post-injection data was compared with the matched-pairs ttest. Results: 31 patients were prospectively evaluated. The mean age of the cohort was 68 years. Sixtyone percent was male. The diagnoses were 18 unilateral vocal fold paralyses, 4 vocal fold pareses, 9 presbylarynx. The mean VHI at entry was 27 (+/- 7.4). This improved to a mean VHI of 18 (+/- 9) at one month postoperatively (p < 0.00) and 19 (+/- 11) at three months (p=0.00). The mean follow-up time was 93 days. There was no evidence of adverse reaction to the implant or procedurerelated complications. Conclusion: Initial data suggests that Novielle Voice Gel is a safe and effective implant for medialization of the vocal folds. Intermediate and long-term follow-up is necessary to ensure enduring safety and efficacy.

AB - Objectives/Hypothesis: There are several implants available for injection medialization of the vocal folds. None are ideal. The purpose of this investigation is to evaluate the safety and efficacy of a new FDA-approved implant for injection augmentation of the vocal folds (Novielle, Coapt Systems Inc, Palo Alto, CA). Study Design: Prospective Cohort Methodology: Individuals undergoing injection augmentation of the vocal folds with Novielle from April 2008 to present were prospectively evaluated and followed. Patients underwent strobovideolaryngoscopy, acoustic analysis, and vocal assessment with the 10-item Voice Handicap Index. Pre- and post-injection data was compared with the matched-pairs ttest. Results: 31 patients were prospectively evaluated. The mean age of the cohort was 68 years. Sixtyone percent was male. The diagnoses were 18 unilateral vocal fold paralyses, 4 vocal fold pareses, 9 presbylarynx. The mean VHI at entry was 27 (+/- 7.4). This improved to a mean VHI of 18 (+/- 9) at one month postoperatively (p < 0.00) and 19 (+/- 11) at three months (p=0.00). The mean follow-up time was 93 days. There was no evidence of adverse reaction to the implant or procedurerelated complications. Conclusion: Initial data suggests that Novielle Voice Gel is a safe and effective implant for medialization of the vocal folds. Intermediate and long-term follow-up is necessary to ensure enduring safety and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=78651501804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651501804&partnerID=8YFLogxK

U2 - 10.1002/lary.21518

DO - 10.1002/lary.21518

M3 - Article

VL - 119

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - SUPPL.3

ER -